Please login to the form below

Not currently logged in
Email:
Password:

dimethyl fumarate

This page shows the latest dimethyl fumarate news and features for those working in and with pharma, biotech and healthcare.

Biogen cuts $217m deal for Karyopharm neurology drug

Biogen cuts $217m deal for Karyopharm neurology drug

Biogen reported 2017 revenues of $12.3bn, up 15% on the prior year, thanks to gains for its multiple sclerosis drugs, particularly Tecfidera (dimethyl fumarate) and rising royalties from Ocrevus (ocrelizumab) -

Latest news

More from news
Approximately 12 fully matching, plus 43 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    Biogen. Patent settlement. Tecfidera (dimethyl fumarate). 1, 250. Merrimack Pharamceuti-cals. Ipsen.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Executive vice president of Biogen leaves Executive vice president of Biogen leaves

    Kingsley joined Biogen in 2010 as senior VP and during his tenure Biogen introduced five new therapies including successfully launching Tecfidera (dimethyl fumarate) – the most prescribed oral treatment for multiple sclerosis.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics